Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | TP53 | P04637 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | GALK1 | P51570 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL964139 | 0.90 | KMT2A (0.48) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL967745 | 0.89 | KMT2A (0.47) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL1010086 | 0.87 | KMT2A (0.48) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL10180610 | 0.85 | TRPV4 (0.49) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL964841 | 0.84 | KMT2A (0.49) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL965594 | 0.84 | KMT2A (0.43) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL10180940 | 0.82 | TRPV4 (0.45) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL1010111 | 0.80 | KMT2A (0.45) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL966062 | 0.80 | MAPT (0.40) | KMT2AMEN1HPGDLMNAPKM | |
| SCHEMBL12946908 | 0.80 | SMN1; SMN2 (0.44) | KMT2AMEN1HPGDLMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | KMT2A 3420/4885MEN1 4049/4885HPGD 2836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.